Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.65 |
| ▸ | IDO1 | P14902 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491077 | 1.00 | TAAR1 (1.00) | TAAR1ADRA1AAOC3IDO1CYP1A2 | |
| Hydrochloric Acid SCHEMBL25232952 | 0.98 | TAAR1 (0.96) | TAAR1ADRA1AAOC3IDO1CYP1A2 | |
| SCHEMBL30284782 | 0.90 | ADRA1A (0.81) | TAAR1ADRA1AAOC3IDO1CYP1A2 | |
| SCHEMBL30284687 | 0.90 | TAAR1 (0.81) | TAAR1ADRA1AAOC3IDO1CYP1A2 | |
| SCHEMBL5663448 | 0.89 | ADRA1A (0.80) | TAAR1ADRA1AAOC3IDO1HTR2A | |
| Ammonia Solution, Strong SCHEMBL1780499 | 0.87 | ADRA1A (0.77) | TAAR1ADRA1AAOC3IDO1HTR2A | |
| SCHEMBL626051 | 0.85 | TAAR1 (0.73) | TAAR1ADRA1ACYP1A2HTR2A | |
| SCHEMBL42578 | 0.84 | ADRA1A (0.72) | TAAR1ADRA1AAOC3IDO1HTR2A | |
| SCHEMBL31284962 | 0.83 | TAAR1 (0.71) | TAAR1ADRA1AAOC3HTR2A | |
| SCHEMBL31166239 | 0.83 | TAAR1 (0.71) | TAAR1ADRA1AAOC3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 483 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117110457-A | Analysis method for screening 50 new pollutants in sewage by micro-volume direct sample injection technology | 司法鉴定科学研究院 | 2023-11-24 | — | — | CN | claimed |
| WO-2023114529-A2 | PHARMACOACTIVE FORMULATIONS FOR DELIVERY OF PSYCHEDELIC COMPOUNDS | BENNES, INC. (US) | 2023-06-22 | — | — | WO | claimed |
| CN-111554440-B | High-strength aluminum alloy power transmission wire | 广西纵览线缆集团有限公司 | 2021-10-29 | — | — | CN | claimed |
| CN-111383790-B | Processing method of aluminum alloy conductor for power transmission | 广西纵览线缆集团有限公司 | 2021-10-29 | — | — | CN | claimed |
| CN-111564243-B | Heat-resistant aluminum alloy conductor | 广西纵览线缆集团有限公司 | 2021-10-29 | — | — | CN | claimed |
| CN-112037966-B | High-strength aluminum alloy conductor | 广西纵览线缆集团有限公司 | 2021-10-08 | — | — | CN | claimed |
| CN-112037991-B | Long-distance aluminum alloy power transmission conductor | 广西纵览线缆集团有限公司 | 2021-10-08 | — | — | CN | claimed |
| CN-111403118-B | Manufacturing process of tensile heat-resistant aluminum alloy conductor | 广西纵览线缆集团有限公司 | 2021-09-07 | — | — | CN | claimed |
| CN-112037991-A | Long-distance aluminum alloy power transmission conductor | 广西纵览线缆集团有限公司 | 2020-12-04 | — | — | CN | claimed |
| CN-112037966-A | High-strength aluminum alloy conductor | 广西纵览线缆集团有限公司 | 2020-12-04 | — | — | CN | claimed |
| EP-1869038-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO-IMIDAZO[1,2-A]PYRIDIN-2-YLAMINE COMPOUNDS AND THEIR USE FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-07-08 | — | — | EP | claimed |
| US-20090137573-A1 | 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments | GRUENENTHAL GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | GRUENENTHAL GMBH (DE) | 2008-12-04 | — | — | US | claimed |
| EP-1180991-A4 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2005-10-12 | — | — | EP | claimed |
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2003-04-24 | — | — | US | claimed |
| US-6462041-B1 | ACTIVATORS OF CASPASE CASCADE; TREATING, PREVENTING OR AMELIORATING NEOPLASIA AND CANCER | CYTOVIA, INC. | 2002-10-08 | — | — | US | claimed |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DISCOVERY PARTNERS INTERNATIONAL, INC. | 2002-05-16 | — | — | US | claimed |
| EP-1180991-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2002-02-27 | — | — | EP | claimed |
| WO-2000044216-A1 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| WO-2000044216-A2 | GAMBOGIC ACID, ANALOGS AND DERIVATIVES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2000-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078292-A1 | Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis | CASP5, CASP3, CASP7 | TAAR1 4047/4885ADRA1A 4001/4885AOC3 4174/4885 |
| US-20080300256-A1 | Substituted 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridin-2-ylamine Compounds and Their Use for Producing Drugs | CYP3A7, CYP3A5, CYP2D6 | TAAR1 1952/4885ADRA1A 39/4885AOC3 3312/4885 |
| US-20020058788-A1 | Facile deprotection of Fmoc protected amino groups | DNPEP, LNPEP, NPEPPS | TAAR1 1082/4885ADRA1A 4454/4885AOC3 2298/4885 |
| US-20090137573-A1 | 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments | OPRL1, TPH1, OPRK1 | TAAR1 60/4885ADRA1A 46/4885AOC3 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.